Prediction of recurrence of non muscle-invasive bladder cancer by means of a protein signature identified by antibody microarray analyses

Proteomics

Volumn 14, Issue 11, 2014, Pages 1333-1342

  Srinivasan, Harish ^a   Allory, Yves ^b   Sill, Martin ^a   Vordos, Dimitri ^b   Alhamdani, Mohamed Saiel Saeed ^a   Radvanyi, Francois ^c   Hoheisel, Jörg D ^a   Schröder, Christoph ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b HENRI MONDOR HOSPITAL   (France)

^c INSTITUT CURIE   (France)

Author keywords

Antibody microarrays; Bladder cancer; Immunoassay; Protein arrays; Proteome analysis; Recurrence

Indexed keywords

CDN1A PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; INTERLEUKIN 8; JUN PROTEIN; LMNA PROTEIN; LYAM1 PROTEIN; MATRIX METALLOPROTEINASE; PROTEIN P21; PROTEIN P53; SMAD3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; YBOX1 PROTEIN; PROTEOME;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; IMMUNOASSAY; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; BLADDER; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PILOT STUDY; PROCEDURES; PROGNOSIS; PROTEIN MICROARRAY; PROTEOMICS; URINARY BLADDER NEOPLASMS;

HUMANS; IMMUNOASSAY; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; PROTEOME; PROTEOMICS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84901826536     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201300320     Document Type: Article

References (75)

1. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62, 10-29.
2. Jacobs, B. L., Lee, C. T., Montie, J. E., Bladder cancer in 2010: how far have we come? CA Cancer J. Clin. 2010, 60, 244-272.
3. Montie, J. E., Clark, P. E., Eisenberger, M. A., El-Galley, R. et al., Bladder cancer. J. Natl. Compr. Canc. Netw. 2009, 7, 8-39.
4. Avritscher, E. B., Cooksley, C. D., Grossman, H. B., Sabichi, A. L. et al., Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006, 68, 549-553.
5. Yabroff, K. R., Lamont, E. B., Mariotto, A., Warren, J. L. et al., Cost of care for elderly cancer patients in the United States. J. Natl. Cancer Inst. 2008, 100, 630-641.
6. Dubosq, F., Ploussard, G., Soliman, H., Turpin, E. et al., Identification of a three-gene expression signature of early recurrence in non-muscle-invasive urothelial cell carcinoma of the bladder. Urol. Oncol. 2012, 30, 833-840.
7. Matsushita, K., Cha, E. K., Matsumoto, K., Baba, S. et al., Immunohistochemical biomarkers for bladder cancer prognosis. Int. J. Urol. 2011, 18, 616-629.
8. Mitra, A. P., Pagliarulo, V., Yang, D., Waldman, F. M. et al., Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J. Clin. Oncol. 2009, 27, 3929-3937.
9. Kramer, M. W., Waalkes, S., Serth, J., Hennenlotter, J. et al., Decreased galectin-8 is a strong marker for recurrence in urothelial carcinoma of the bladder. Urol. Int. 2011, 87, 143-150.
10. Jeong, P., Min, B. D., Ha, Y. S., Song, P. H. et al., RUNX3 methylation in normal surrounding urothelium of patients with non-muscle-invasive bladder cancer: potential role in the prediction of tumor progression. Eur. J. Surg. Oncol. 2012, 38, 1095-1100.
11. van Rhijn, B. W., Lurkin, I., Radvanyi, F., Kirkels, W. J. et al., The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 2001, 61, 1265-1268.
12. Hernandez, S., Lopez-Knowles, E., Lloreta, J., Kogevinas, M. et al., Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J. Clin. Oncol. 2006, 24, 3664-3671.
13. Andreasson, U., Ek, S., Merz, H., Rosenquist, R. et al., B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule. Cancer Lett. 2008, 259, 138-145.
14. Dexlin, L., Ingvarsson, J., Frendeus, B., Borrebaeck, C. A., Wingren, C., Design of recombinant antibody microarrays for cell surface membrane proteomics. J. Proteome Res. 2008, 7, 319-327.
15. Sara, E., Borrebaeck, C. A., Parallel gene expression profiling of mantle cell lymphoma-how do we transform 'omics data into clinical practice. Curr. Genomics 2007, 8, 171-179.
16. Wilson, S. K., Adjeroud, M., Bellwood, D. R., Berumen, M. L. et al., Crucial knowledge gaps in current understanding of climate change impacts on coral reef fishes. J. Exp. Biol. 2010, 213, 894-900.
17. Babjuk, M., Oosterlinck, W., Sylvester, R., Kaasinen, E. et al., EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 2008, 54, 303-314.
18. Babjuk, M., Oosterlinck, W., Sylvester, R., Kaasinen, E. et al., EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur. Urol. 2011, 59, 997-1008.
19. Schröder, C., Jacob, A., Tonack, S., Radon, T. P. et al., Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies. Mol. Cell. Proteomics 2010, 9, 1271-1280.
20. Brennan, D. J., O'Connor, D. P., Rexhepaj, E., Ponten, F., Gallagher, W. M., Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat. Rev. Cancer 2010, 10, 605-617.
21. Hoheisel, J. D., Alhamdani, M. S., Schroder, C., Affinity-based microarrays for proteomic analysis of cancer tissues. Proteomics Clin. Appl. 2013, 7, 8-15.
22. Schröder, C., Alhamdani, M. S., Fellenberg, K., Bauer, A. et al., Robust protein profiling with complex antibody microarrays in a dual-colour mode. Methods Mol. Biol. 2011, 785, 203-221.
23. Alhamdani, M. S., Schröder, C., Hoheisel, J. D., Analysis conditions for proteomic profiling of mammalian tissue and cell extracts with antibody microarrays. Proteomics 2010, 10, 3203-3207.
24. Schmidt, R., Jacak, J., Schirwitz, C., Stadler, V. et al., Single-molecule detection on a protein-array assay platform for the exposure of a tuberculosis antigen. J. Proteome Res. 2011, 10, 1316-1322.
25. Smyth, G. K., Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3, Article3.
26. Sill, M., Schröder, C., Hoheisel, J. D., Benner, A., Zucknick, M., Assessment and optimisation of normalisation methods for dual-colour antibody microarrays. BMC Bioinform. 2010, 11, 556.
27. Smyth, G. K., Michaud, J., Scott, H. S., Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 2005, 21, 2067-2075.
28. Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B 1995, 57, 289-300.
29. Breiman, L., Random Forests. Mach. Learn. 2001, 45, 5-32.
30. Slawski, M., Daumer, M., Boulesteix, A. L., CMA: a comprehensive Bioconductor package for supervised classification with high dimensional data. BMC Bioinform. 2008, 9, 439.
31. Rustici, G., Kolesnikov, N., Brandizi, M., Burdett, T. et al., ArrayExpress update-trends in database growth and links to data analysis tools. Nucleic Acids Res. 2013, 41, D987-D990.
32. Huang da, W., Sherman, B. T., Lempicki, R. A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4, 44-57.
33. Kanehisa, M., Goto, S., Sato, Y., Furumichi, M., Tanabe, M., KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012, 40, D109-D114.
34. Franceschini, A., Szklarczyk, D., Frankild, S., Kuhn, M. et al., STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013, 41, D808-D815.
35. Sanchez-Carbayo, M., Socci, N. D., Lozano, J. J., Haab, B. B., Cordon-Cardo, C., Profiling bladder cancer using targeted antibody arrays. Am. J. Pathol. 2006, 168, 93-103.
36. Schiffer, E., Vlahou, A., Petrolekas, A., Stravodimos, K. et al., Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin. Cancer Res. 2009, 15, 4935-4943.
37. Ouyang, X., Jessen, W. J., Al-Ahmadie, H., Serio, A. M. et al., Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res. 2008, 68, 2132-2144.
38. Chadalapaka, G., Jutooru, I., Burghardt, R., Safe, S., Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol. Cancer Res. 2010, 8, 739-750.
39. Chadalapaka, G., Jutooru, I., Chintharlapalli, S., Papineni, S. et al., Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res. 2008, 68, 5345-5354.
40. Jutooru, I., Chadalapaka, G., Sreevalsan, S., Lei, P. et al., Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp. Cell Res. 2010, 316, 2174-2188.
41. Karam, J. A., Lotan, Y., Karakiewicz, P. I., Ashfaq, R. et al., Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007, 8, 128-136.
42. Jonges, L. E., Nagelkerke, J. F., Ensink, N. G., van der Velde, E. A. et al., Caspase-3 activity as a prognostic factor in colorectal carcinoma. Lab Invest. 2001, 81, 681-688.
43. Huang, Q., Li, F., Liu, X., Li, W. et al., Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat. Med. 2011, 17, 860-866.
44. Konstantinidou, A. E., Givalos, N., Gakiopoulou, H., Korkolopoulou, P. et al., Caspase-3 immunohistochemical expression is a marker of apoptosis, increased grade and early recurrence in intracranial meningiomas. Apoptosis 2007, 12, 695-705.
45. Xie, W., Bharathy, S., Kim, D., Haffty, B. G. et al., Frequent alterations of SMAD signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. Oncol Res. 2003, 14, 61-73.
46. Alazzouzi, H., Alhopuro, P., Salovaara, R., Sammalkorpi, H. et al., SMAD4 as a prognostic marker in colorectal cancer. Clin. Cancer Res. 2005, 11, 2606-2611.
47. Xie, W., Mertens, J. C., Reiss, D. J., Rimm, D. L. et al., Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res. 2002, 62, 497-505.
48. Grossman, H. B., Messing, E., Soloway, M., Tomera, K. et al., Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005, 293, 810-816.
49. Konstantakou, E. G., Voutsinas, G. E., Karkoulis, P. K., Aravantinos, G. et al., Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Int. J. Oncol. 2009, 35, 401-416.
50. Stravopodis, D. J., Karkoulis, P. K., Konstantakou, E. G., Melachroinou, S. et al., Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines. Int. J. Oncol. 2009, 34, 137-160.
51. To, K., Fotovati, A., Reipas, K. M., Law, J. H. et al., Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res. 2010, 70, 2840-2851.
52. Gluz, O., Mengele, K., Schmitt, M., Kates, R. et al., Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J. Clin. Oncol. 2009, 27, 6144-6151.
53. Ling, Y., Chunli, L., Xiaohou, W., Qiaoling, Z., Involvement of the PLCepsilon/PKCalpha pathway in human BIU-87 bladder cancer cell proliferation. Cell Biol. Int. 2011, 35, 1031-1036.
54. Ching, C. B., Hansel, D. E., Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab. Invest. 2010, 90, 1406-1414.
55. Bonin, S., Brunetti, D., Benedetti, E., Dotti, I. et al., Molecular characterisation of breast cancer patients at high and low recurrence risk. Virchows Arch 2008, 452, 241-250.
56. Gallagher, E. M., O'Shea, D. M., Fitzpatrick, P., Harrison, M. et al., Recurrence of urothelial carcinoma of the bladder: a role for insulin-like growth factor-II loss of imprinting and cytoplasmic E-cadherin immunolocalization. Clin. Cancer Res. 2008, 14, 6829-6838.
57. Negraes, P. D., Favaro, F. P., Camargo, J. L., Oliveira, M. L. et al., DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection. BMC Cancer 2008, 8, 238.
58. Alvaro, T., Lejeune, M., Salvado, M. T., Bosch, R. et al., Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res. 2005, 11, 1467-1473.
59. Penuelas, S., Anido, J., Prieto-Sanchez, R. M., Folch, G. et al., TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009, 15, 315-327.
60. Poncelet, A. C., Schnaper, H. W., Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2(I) collagen expression in human glomerular mesangial cells. J. Biol. Chem. 2001, 276, 6983-6992.
61. van Duin, M., van Marion, R., Vissers, K., Watson, J. E. et al., High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer 2005, 44, 438-449.
62. Shariat, S. F., Karakiewicz, P. I., Ashfaq, R., Lerner, S. P. et al., Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008, 112, 315-325.
63. Shariat, S. F., Zlotta, A. R., Ashfaq, R., Sagalowsky, A. I., Lotan, Y., Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod. Pathol. 2007, 20, 445-459.
64. St Hill, C. A., Interactions between endothelial selectins and cancer cells regulate metastasis. Front Biosci. 2011, 17, 3233-3251.
65. Cinghu, S., Anandharaj, A., Lee, H. C., Yu, J. R., Park, W. Y., FTS (fused toes homolog) a novel oncoprotein involved in uterine cervical carcinogenesis and a potential diagnostic marker for cervical cancer. J. Cell Physiol. 2011, 226, 1564-1572.
66. Yotov, W. V., Hamel, H., Rivard, G. E., Champagne, M. A. et al., Amplifications of DNA primase 1 (PRIM1) in human osteosarcoma. Genes Chromosomes Cancer 1999, 26, 62-69.
67. Qiu, J., Choi, G., Li, L., Wang, H. et al., Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J. Clin. Oncol. 2008, 26, 5060-5066.
68. Martino, J. J., Wall, B. A., Mastrantoni, E., Wilimczyk, B. J. et al., Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells. Oncogene 2013, 32, 4366-4376.
69. Speyer, C. L., Smith, J. S., Banda, M., DeVries, J. A. et al., Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res. Treat 2012, 132, 565-573.
70. Louhelainen, J. P., Hurst, C. D., Pitt, E., Nishiyama, H. et al., DBC1 re-expression alters the expression of multiple components of the plasminogen pathway. Oncogene 2006, 25, 2409-2419.
71. Knowles, M. A., Shaw, M. E., Proctor, A. J., Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene 1993, 8, 1357-1364.
72. Ikegaki, N., Gotoh, T., Kung, B., Riceberg, J. S. et al., De novo identification of MIZ-1 (ZBTB17) encoding a MYC-interacting zinc-finger protein as a new favorable neuroblastoma gene. Clin. Cancer Res. 2007, 13, 6001-6009.
73. Iraci, N., Diolaiti, D., Papa, A., Porro, A. et al., A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res. 2011, 71, 404-412.
74. Lee, A. J., Roylance, R., Sander, J., Gorman, P. et al., CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. J. Pathol. 2012, 226, 482-494.
75. Tung, J. N., Tsao, T. Y., Tai, C. J., Yeh, K. T. et al., Distribution of lysosome-associated membrane proteins-1 and -2, and cathepsin D in eosinophilic granular bodies: possible relationship to cyst development in pilocytic astrocytomas. J. Int. Med. Res. 2010, 38, 1354-1364.